Posted by Michael Wonder on 10 Aug 2016
Cancer patients may lose vital drug in crackdown on funding: watchdog reviews 31 treatments that are not usually available on the NHS
10 August 2016 - The drug brentuximab vedotin may no longer be provided on the NHS.
Patients with a devastating form of lymphoma are set to be the first to fall foul of an overhaul of the Cancer Drugs Fund.
NHS drugs watchdog NICE is reviewing all 31 treatments that were previously provided via the Fund, in a bid to rein in spending.
In a draft decision published today, officials recommend that the drug brentuximab vedotin no longer be provided on the NHS.
